Abstract
Nanotechnology has emerged as a promising strategy toward inflammatory bowel disease (IBD) treatment. Nano-sized drug delivery systems exhibit an increased accumulation in inflamed tissues due to their nanometer size and present the ability to overcome the challenging inflamed colonic barriers (i.e. thick mucus layer, disrupted epithelium, altered colonic transit time). Moreover, nanocarriers are able to increase the amount of drug present at the colonic site decreasing their associated systemic side effects and increasing their efficacy. This review aims to analyze the nanoparticulate systems that have been evaluated for IBD treatment based on (i) the strategy followed towards an increased colonic accumulation and/or permeation, (ii) the small or biopharmaceutical antiinflammatory drug encapsulated within the nanocarriers and (iii) the polymer(s) used for their preparation, highlighting the profits and the drawbacks of each of the candidates based on reported results.
Keywords: Inflammatory bowel disease, colitis, nanoparticles, PLGA, chitosan, TMC, colon targeting.
Current Pharmaceutical Design
Title:Targeting Inflammatory Bowel Diseases by Nanocarriers Loaded with Small and Biopharmaceutical Anti-Inflammatory Drugs
Volume: 22 Issue: 40
Author(s): Ana Beloqui, Régis Coco and Véronique Préat
Affiliation:
Keywords: Inflammatory bowel disease, colitis, nanoparticles, PLGA, chitosan, TMC, colon targeting.
Abstract: Nanotechnology has emerged as a promising strategy toward inflammatory bowel disease (IBD) treatment. Nano-sized drug delivery systems exhibit an increased accumulation in inflamed tissues due to their nanometer size and present the ability to overcome the challenging inflamed colonic barriers (i.e. thick mucus layer, disrupted epithelium, altered colonic transit time). Moreover, nanocarriers are able to increase the amount of drug present at the colonic site decreasing their associated systemic side effects and increasing their efficacy. This review aims to analyze the nanoparticulate systems that have been evaluated for IBD treatment based on (i) the strategy followed towards an increased colonic accumulation and/or permeation, (ii) the small or biopharmaceutical antiinflammatory drug encapsulated within the nanocarriers and (iii) the polymer(s) used for their preparation, highlighting the profits and the drawbacks of each of the candidates based on reported results.
Export Options
About this article
Cite this article as:
Beloqui Ana, Coco Régis and Préat Véronique, Targeting Inflammatory Bowel Diseases by Nanocarriers Loaded with Small and Biopharmaceutical Anti-Inflammatory Drugs, Current Pharmaceutical Design 2016; 22 (40) . https://dx.doi.org/10.2174/1381612822666160211141813
DOI https://dx.doi.org/10.2174/1381612822666160211141813 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Optimization of Time Controlled 6-mercaptopurine Delivery for Site- Specific Targeting to Colon Diseases
Current Drug Delivery Recent Advances in the Structure-Based and Ligand-Based Design of IKKβ Inhibitors as Anti-inflammation and Anti-cancer Agents
Current Medicinal Chemistry Validation and Development of N-glycan as Biomarker in Cancer Diagnosis
Current Pharmacogenomics and Personalized Medicine ABC Transporters as Potential Targets for Modulation of Drug Resistance
Mini-Reviews in Medicinal Chemistry Eicosanoids in Prevention and Management of Diseases
Current Molecular Medicine Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects
Current Pharmaceutical Biotechnology Identification of an MiRNA-mRNA Regulatory Network in Colorectal Cancer
Combinatorial Chemistry & High Throughput Screening Anticancer Potential of Pulicaria crispa Extract on Human Breast Cancer MDA-MB-231 Cells
Letters in Drug Design & Discovery Gender Differences in P-Glycoprotein Expression and Function: Effects on Drug Disposition and Outcome
Current Drug Metabolism Development of Nucleic Acid Drugs for Neurological Disorders
Current Topics in Medicinal Chemistry Anti-Tuberculosis Drug Induced Hepatotoxicity and Genetic Polymorphisms in Drug-metabolizing Genes
Current Pharmacogenomics Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Mechanisms for Targeted Delivery of Nanoparticles in Cancer
Current Pharmaceutical Design Pyridine Based Antitumour Compounds Acting at the Colchicine Site
Current Medicinal Chemistry Multifaceted Role of Neuropilins in Cancer
Current Medicinal Chemistry The Role of DNA-Microarray in Translational Cancer Research
Current Pharmacogenomics Interaction Between Retinoids and Eicosanoids: Their Relevance to Cancer Chemoprevention
Current Nutrition & Food Science Epigenetic Interventions Increase the Radiation Sensitivity of Cancer Cells
Current Pharmaceutical Design The Blood-Brain/Tumor Barriers: Challenges and Chances for Malignant Gliomas Targeted Drug Delivery
Current Pharmaceutical Biotechnology Detection of Hepatitis B Virus-associated Hepatocellular Carcinoma Disease Using Hybrid Hierarchical k-Means Clustering and SVM Algorithm
Current Bioinformatics